Background: Rapid progressors are exposed to HIV infection at an early stage of life, and the prognosis is poor without treatment. Reducing the proportion of infants who are rapid progressors, require strengthening strategies to achieve the highest level of performance for the PMTCT program.
Introduction
The proportion of HIV-infected who are rapid progressor has decreased with the improvement of the quality of Prevention of Mother to Child Transmission (PMTCT), and more specifically with early management of the mother and child (1) . In 2011, the demographic health survey conducted in Cameroon showed that the HIV seroprevalence in women aged 15-49 years who were pregnant during the survey was 5.6% (2) . However, the performance level of the PMTCT program is rather low nationwide, with only 21.4% of the HIV infected pregnant women receiving anti-retroviral (ARV) prophylaxis (3) . Many HIV exposed infants born to mothers who have
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Obstetrical, maternal characteristics and outcome of HIV-infected rapid progressor infants at Yaounde: a retrospective study received PMTCT interventions may have missed out some of the interventions that target infants. In fact, about 74.3% of infants did not receive any ARV prophylaxis according to the report of the ministry of public health (3) . A study carried out in the Eastern Region of Cameroon showed that 65.2% of exposed infants and 91.1% of mothers did not receive any ARV prophylaxis for PMTCT (4) .
Pediatric HIV infection is most often transmitted vertically , either during pregnancy, delivery or during breastfeeding (5) (6) (7) (8) (9) (10) . Newell et al. found that without any intervention, 35 .2% of HIV infected children will die at the end of the first year and 52.5% by two years in resource limited countries (11) . Before that Blanche et al. showed that 44% of HIV-1 infected infants born to mothers with severe disease at delivery, will die during the first 18 months of life as a result of HIV encephalopathy and opportunistic infections (12) . Rapid progressors are infants who develop severe signs of AIDS very early in life usually leading to death for most of them (13, 14) . Many factors are described in literature concerning HIV-infected rapid progressors (15) (16) (17) (18) . It has been proven that there is a relationship between high maternal viral load and severe immunodeficiency, and high viral load in infants (15, (19) (20) (21) (22) . The severity of immunosuppression, and high viral loads in infants (23) (24) (25) are associated with rapid progression of HIV infection. On the contrary, maternal treatment even with prophylactic regimen, would indirectly reduce the progression of the disease in the infant (15, 16, 19, 26) . Some associated factors could be found in our milieu because of concurrent illness. The objective of our study was to explore factors which can help in diagnosing rapid progressor children and their outcome.
Methods

Study framework
A retrospective study was carried out to identify rapid progressor infants seen between January 2010 and February 2012 at the Mother and Child Centre of the Chantal Biya Foundation (CME-CBF). The CME-CBF is a pediatric centre which handles the largest cohort of children on ARVs in Cameroon. HIV testing of children less than 18 months was done using DNA/RNA PCR. The PCR was done at the Centre Pasteur du Cameroun in the framework of the ANRS Pediacam study (27) and at the Chantal Biya International Research Center (CBIRC) (28) . The children were referred to the CME-FCB either for diagnosis of HIV in those suspected to be infected or for further management of the already diagnosed HIV infection. The others were HIV exposed infants followed up in PMTCT. Patients are managed at the study site following the national guidelines for HIV exposed and infected children (29) .
Study population
HIV-infected infants less than 12 months old received and followed up at the HIV treatment centere of the CME-FCB were included in this study. We excluded asymptomatic HIV-infected subjects with no available CD4 count and also exposed infants of HIV-infected mothers without PCR result.
Procedure and data collection
We reviewed the medical records of the HIV-infected children from the database of the site. According to our inclusion criteria, we selected those in whom the signs and symptoms corresponded to stage 4 of the WHO classification or who had CD4 counts below 25% no matter their clinical stage, whether they had been on ARV therapy or not. Mothers or guardians who accompanied their infants to routine consultations were interviewed on the pregnancy that led to the birth of the child. Data which could not be obtained from mothers' interview (mothers who died or were absent) were collected from the medical records of the patients. Reasons why PMTCT was not carried out were sought. We collected socio-demographic data of the mothers such as: age, level of education, social status. We then obtained information concerning the maternal obstetrical history. This was the number of antenatal clinics (ANCs) attended, the existence of any pathologies during the pregnancy and PMTCT measures carried out, as well as the perinatal history. We also found out about cases of death of siblings.
Concerning the infants, we recorded their age, sex, immunization status, the psychomotor development, comorbid conditions and prior hospitalisations. We also evaluated their nutritional status and found out whether they received Cotrimoxazole and ARV prophylaxis, feeding practices, biological analysis (CD4 count, and viral load). his first year of life, a sign which classifies him in clinical stage 3 or 4 or a severe immunodeficiency (% CD4 <25) or both (30) . Patients survival during the study period was evaluated. We then estimated their probability of survival with or without ARV treatment from birth to the end of the study using the Kaplan-Meier method.
Main outcome and other variables definitions
Other variables as mentioned above were used. The feeding method were defined as; infant formula feeding, breastfeeding or mixed when other food, solid or liquid was given in addition to breast milk. Protected breastfeeding was described when the mother was receiving or had received prophylactic ARVs and as well as the infant, for up to one week following the end of the breastfeeding. Their clinical and immunological stages were determined using the WHO classification. Infants were divided into two groups; minor immunodeficiency (those in stage 1 and 2), and major immunodeficiency (those in stages 3 and 4).
Statistical analysis
Data was analysed using the Epi Info 7 software and Microsoft Excel 2010. Through the univariate analysis of maternal and infant characteristics, we described the categorical variables in frequencies and percentages. Medians and interquartile ranges were used for continuous variables. Bivariate analysis consisted of estimating the odds ratio measuring the obstetrical, mothers and infants characteristics of the HIV-infected rapid progressors within the 95% confidence intervals. We use the Log-rank test to calculate P value which we analysed. P values <0.05 were considered statistically significant.
Ethical considerations
Our study was approved by the Institutional Ethics and Research Committee of the Faculty of Medicine and Biomedical Sciences of the University of Yaounde I. A written or verbal informed consent was obtained from parents or guardians prior to their interview and data collection. Both clinical records and laboratory results were kept confidential.
Results
Socio-demographic data
In all, 462 HIV-1-infected children were received on site during the study period; no case of HIV-2 was recorded. Among the subjects, we identified 176 HIV-1 infected infants aged less than 12 months. Of the 150/(32.5%) HIVinfected children who fulfilled our inclusion criteria, 85.2% of them were rapid progressors ( Figure 1) . The median age Table 1 ). Most of the children who were rapid progressor 80.7% (121/150) had siblings with 50.7% of them having more than 3 siblings. In 11.3% of cases, there was a history of death of a sibling occurring between the ages of 3 to 16 months with a median age of 8 months; their HIV status as well as that of their mothers were unknown at the time of death.
Antenatal history and prevention of mother to child transmission of HIV (PMTCT)
Most of the mothers interviewed (65.4%) started ANC during the second trimester, others either during the first (11.3%) or the third (17.3%) trimester, while some (6%) never attended ANC. About 47.2% (62/131) of mothers were hospitalized during their pregnancy because of one or a combination of pathologies including gastroenteritis (59.7%), pulmonary infections (48.4%), malaria (43.5%); genital and urinary tract infections (20.9%) and pulmonary tuberculosis (19.4%). PMTCT measures were not carried out in 2/3 of these mothers, 105 pregnant women (70.0%) did not take any ARV prophylaxis. Most of them did not know their HIV status. The status for 80 (53.3%) of them was discovered after delivery, and for others when the child was ill. Twenty three mothers (15.3%) knew their HIV status before pregnancy, 35 (23.3%) during pregnancy with 2%, 14.7% and 8.7% during the first, the second and the third trimester respectively. Nine (6.0%) were informed at delivery ( Table 1) . Ignorance of their HIV status, denial of the test results and no ARVs given by health care providers were some of the reasons given for the absence of ARV prophylaxis. Of the 45 mothers who received ARVs, 15 (33.3%) were on HAART, 9 of whom started ARV before; 5 during pregnancy and 1 after childbirth. Others CD4 counts performed during pregnancy were reported and these showed a severe immunodeficiency with CD4 count <200/mm 3 for 12 of them (29.3%).
Significant maternal factors associated with subjects were the low level of education (OR=3.87; P=0.016), CD4 count less than 200/mm 3 during pregnancy (OR=43.3; P=0.000), absence of ARV prophylaxis (OR=6.02; P=0.043), or treatment with HAART (OR=5.74; P=0.000).
Characteristics of the rapid progressor infants
At enrolment, 87 infants (58.0%) were in clinical stage 4 while the others were selected based on severe immune deficiency. The viral load was available only in 79 (52.7%) infants and the values ranged between 111.3 and 663 log 10 copies/mL with an average of 87.7 log 10 copies/mL. Only 39 rapid progressors (26.0%) had received ARV prophylaxis at birth ( Table 2) , more than 3/4 (76.9%) of whom had been on bitherapy with Zidovudine and Nevirapine, the rest received monotherapy; 12.8% received Nevirapine and 10.7% Zidovudine.
In infants, the most significant events were the absence of Cotrimoxazole prophylaxis (OR=11.61; P=0.000) and antiretroviral prophylaxis (OR=2.70; P=0.0344); ( Table 3) .
Outcome of the rapid progressors
Death occurred in 52/150 (34.7%) of the patients during the study period, at a median age of 7 months ( Table 4 ). The survival rate was higher (84.3%) in infants who were receiving ARV treatment (P<0.05) as opposed to 43.3% in those who were not (Figure 2) . ARV, anti-retroviral. 
Discussion
This retrospective study described the HIV-infected rapid progressors with regards to the mothers' obstetrical characteristics and those of the children. The proportion of the rapid progressor was high in our study. Our study has not been performed on a cohort of infant. We recruited at a specialized HIV/AIDS unit where most of the children were symptomatic at referral. Most of them came either from our admission units or from others health facilities for confirmation of their HIV status or for follow up. Some were HIV exposed infants followed in the PMTCT unit. These could have introduced some bias.
We found patients at clinical stage 1 & 2 with a severe immunological deficiency (CD4 count <25%). Some had severe clinical stage but no profound immune-depression.
We also described the socio-demographic background of the mother and infant couple and found out whether they benefited from PMTCT interventions. Only 12.2% of the mothers were employed. The socio-demographic conditions were poor for many; in fact, 12.7%, 8.7% and 2.7% of infants had lost their mothers, fathers or both parents respectively. Such conditions increase the vulnerability of the subjects to illnesses and death (31) . The maternal factors that were significantly associated with advanced WHO clinical stage of the rapid progressors w e r e a C D 4 c o u n t < 2 0 0 / m m 3 , a b s e n c e o f A RV s prophylaxis or not being on HAART. Previous studies have shown that severe immune deficiency in mothers was associated with early poor progression of the HIV in infants (16, 32) . The same would be true with a high maternal viral load during delivery (33, 34) . Ideally, testing of women of child-bearing age and pregnant women could permit early HIV screening and the initiation of ARV treatment or the PMTCT program in case of infection. Early detection of HIV infection in mothers as from the 14 th week of gestation and of every exposed child at birth are cost-effective (35) . In our study, 65.4% of the pregnant women started ANC during the second trimester and 53.3% had their HIV screening performed after delivery and for some when the children were ill. Hence, most (70.0%) of them did not receive any ARV prophylaxis during pregnancy meanwhile its effectiveness has been proven in the reduction of the rate of rapid disease progression in children (15, 16, 19, 26) . Thus, the rapid progressors seem to be particularly associated with such situations in our study (OR=6.02; P=0.043). It has been demonstrated that HAART is more effective in the prevention of severe clinical forms in children than ARV prophylaxis (11, 15) . In our population however, the benefits of HAART during pregnancy was not remarkably associated with rapid progressor infants. Only 15 women received HAART during pregnancy ( Table 1) . We did not investigate the existence of a relationship between the onset of treatment and the gestational age. One could imagine cases in which the HAART had not yet induced significant effects on the immunity of some mothers, particularly those who were severely immunocompromised during the pregnancy. Analysis of rapid progressors' specific conditions revealed an association between the absence of prophylaxis with cotrimoxazole (P=0.000, OR=11.61), or ARVs (P=0.0344, OR=2.70), and the severity of the clinical and immunological presentation in this study. Indeed, cotrimoxazole can Transl Pediatr 2016;5(2):46-54 tp.amegroups.com prevent under certain conditions, severe infections in infants infected with HIV. It can reduce mortality by 43% and hospitalizations by 23% (36, 37) .
The mortality rate was higher (34.7%) in our population ( Table 4 ), compared to that found in Nepal (38) . It others setting very high mortality rate where found in infants who were not on ARV compared to those receiving ARV treatment (14) . Death occurred in our study at a median age of 7 months; HIV infection increased the death rate before the age of 2 years considerably (39, 40) . The survival rate was low (43.3%) in children who were not treated, against 84.3% in those on ARV treatment. It has been demonstrated that HAART increases survival in approximately 95% of patients; meanwhile, death is almost inevitable for those without treatment (41) . For this reason, authors suggested that HAART should be given as early as possible for all HIV-infected children (1, 13, 42) .
Conclusions
In our study, mothers were often not aware of their HIV status and some did not have access to PMTCT services. According to authors, such mothers constitute a target population, for whom early diagnosis of their children is important (43) . HAART before pregnancy for women eligible to treatment would improve their CD4 count before pregnancy. It must be associated to cotrimoxazole and ART prophylaxis in infants, as well as HAART in infant with a positive PCR in order to improve their survival rate.
